Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M.
Grubmüller B, et al. Among authors: hacker m.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19.
Eur J Nucl Med Mol Imaging. 2019.
PMID: 30569186
Free PMC article.